Recce Ltd has released a press release.
Recce Selects CMAX for Phase I/II UTI Clinical Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- A$6.21m Received from R&D Rebate Payments
- JP Morgan Healthcare Conference
- Australian Patent to be Granted for RECCE Anti-Infectives
- Anti-Infective Research Unit est. at Murdoch Childrens
- Approval to Start Phase I/II Diabetic Foot Ulcer Study
Later from Recce Pharmaceuticals
- Corporate Presentation - WI Emergence 2023
- Recce Receives Further A$973,144 R&D Advance
- New Family 4 Patent to be Granted for RECCE Anti-Infectives
- Ethics Approval to Start Phase I/II (I.V.) Clinical Trial
- Ethics Approval for Phase I/II UTI Trial Expansion
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals